HOME > COMMENTARY

COMMENTARY

March 24, 2003
January 20, 2003
< Special Contribution >

January 13, 2003
BARKER ON DRUGS

December 23, 2002
BARKER ON DRUGS (10)

November 18, 2002
BARKER ON DRUGS (9)

October 14, 2002
Commentary 2 articles

October 7, 2002
Barker on Drugs (8)

September 9, 2002
Barkers on Drugs (7)

July 29, 2002
BARKER ON DRUGS (6) Great Results, Shame about the Forecasts

June 24, 2002
BARKER ON DRUGS(5)

June 3, 2002
BARKER ON DRUGS(4)

April 22, 2002
Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -

April 22, 2002
BARKER ON DRUGS (3)

March 11, 2002
BARKER ON DRUGS

February 18, 2002
Comarketing as a Marketing Strategy Option -1-

January 21, 2002
Comarketing as a Marketing Strategy Option -2-

January 21, 2002
Barker on Drugs (1)

January 14, 2002
Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan

July 9, 2001
< Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-

May 21, 2001

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

By Sakura Kono

Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…